Zobrazeno 1 - 10
of 14
pro vyhledávání: '"M G, Jannuzzo"'
Autor:
Elio M. Vinci, Armando Santoro, Giordano Vitali, Mariangela Mariani, Rossana Berardi, Scott T. Tagawa, Hielke J. Meulenbeld, Ronald de Wit, Luigi Dogliotti, Jean P. Bleuse, Cora N. Sternberg, Federico Cappuzzo, Eric Raymond, Anna Petroccione, M. G. Jannuzzo
Publikováno v:
BJU International. 111:44-52
What's known on the subject? and What does the study add? Since their discovery aurora kinases have been identified as a potential target in anticancer therapy and currently many aurora-selective small molecule kinase inhibitors are in development. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91696ec7bbe40ab7c56215ea468c48f8
https://doi.org/10.1111/j.1464-410x.2012.11404.x
https://doi.org/10.1111/j.1464-410x.2012.11404.x
Autor:
M. Schena, S. Crippa, A. Petroccione, S. Comis, Carlo Barone, Steven D. Weitman, R. MacArthur, Marco Merlano, G. Fornari, F. Fiorentini, Domenica Lorusso, M. G. Jannuzzo, Mario Airoldi, F. Caponigro
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:389-394
Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a363b84f7228600856eee4442857cd4d
https://doi.org/10.1007/s00280-009-1175-6
https://doi.org/10.1007/s00280-009-1175-6
Autor:
M. G. Jannuzzo, Jean-Pierre Delord, Patrick Schöffski, Giovanni Scambia, Anna Petroccione, C. Davite, Thomas Gauler, M.J.A. de Jonge, Armando Santoro, Benjamin Besse
Publikováno v:
Annals of Oncology, 26(3), 598-607. Elsevier Ltd.
According to the results of this multi-tumour, multi-institutional Simon two-stage design phase II study the aurora kinase inhibitor danusertib was found to have only limited anti-tumour activity in heavily pre-treated patients with breast, ovarian,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff3f37b1378f2e404fa1c3c2eee7688
https://lirias.kuleuven.be/handle/123456789/490090
https://lirias.kuleuven.be/handle/123456789/490090
Autor:
P. Duchene, M. G. Jannuzzo, J. P. Laneury, Georges Houin, J. C. Fleishaker, P. Rampal, A. Tran
Publikováno v:
Clinical Drug Investigation. 19:473-477
Objective: Reboxetine is a unique selective norepinephrine (noradrenaline) reuptake inhibitor (selective NRI) that is effective and well tolerated at a dosage of 8 to 10 mg/day in the short- and long-term treatment of depression. The objective of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f99feb687e311a8cf519496ba85563db
https://doi.org/10.2165/00044011-200019060-00010
https://doi.org/10.2165/00044011-200019060-00010
Publikováno v:
Biopharmaceuticsdrug disposition. 20(4)
Reboxetine is a racemic mixture of FCE 22071 and FCE 21684 enantiomers. The pharmacokinetics of the enantiomers of reboxetine were observed to be linear in male healthy subjects (n = 6) after the administration of 1.5, 3, 4.5 mg dose of reboxetine as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3dcbc7aa889ee81e11fbdb11452d39b
https://pubmed.ncbi.nlm.nih.gov/10440792
https://pubmed.ncbi.nlm.nih.gov/10440792
Autor:
Mario Airoldi, Giovanni Scambia, D. Lorusso, G. Fornari, M. Schena, M. Quirino, Marco Merlano, S. Crippa, M. G. Jannuzzo, F. Caponigro
Publikováno v:
European Journal of Cancer Supplements. 5:111-112
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6af024eb1156bd9ae5243ee525a0966
https://doi.org/10.1016/s1359-6349(07)70514-1
https://doi.org/10.1016/s1359-6349(07)70514-1
Autor:
Armando Santoro, M. G. Jannuzzo, Cristina Davite, Silvia Novello, Ahmad Awada, Jean-Pierre Delord, Wilfried Eberhardt, Maja J.A. de Jonge, Maurizio Nicodemo, Thomas Gauler, Paolo Marchetti, Anna Petroccione, Mariangela Mariani, Pierfranco Conte, Benjamin Besse, Egbert F. Smit, Roberta Ceruti, Carlo Barone, Elizabeth Ruth Plummer
Publikováno v:
Publons
ResearcherID
ResearcherID
e19138 Background: D is an ATP competitive pan-aurora kinases inhibitor with activity also against FGFRs, VEGFR, Ret, TrkA, Scr, and Abl. Methods: Eligible pts had NSCLC progressing for advanced/metastatic disease after 1 prior chemotherapy line (CT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df103af382c37d1fe47901cf6d01fbfb
https://doi.org/10.1200/jco.2013.31.15_suppl.e19138
https://doi.org/10.1200/jco.2013.31.15_suppl.e19138
Autor:
G. Vitali, Hielke J. Meulenbeld, E. M. Vinci, M. G. Jannuzzo, Eric Raymond, Luigi Dogliotti, Armando Santoro, Cora N. Sternberg, Scott T. Tagawa, Federico Cappuzzo, J. P. Bleuse, R. de Wit, Mariangela Mariani, Anna Petroccione, Rossana Berardi
Publikováno v:
Journal of Clinical Oncology. 29:4628-4628
4628 Background: D is a small molecule that inhibits Aurora kinases, proteins regulating mitosis, implicated in tumorigenesis and overexpressed in prostate cancer. After D administration, tumor reg...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61f509fe305e5294706437137b477409
https://doi.org/10.1200/jco.2011.29.15_suppl.4628
https://doi.org/10.1200/jco.2011.29.15_suppl.4628
Autor:
M. G. Jannuzzo, Michela Maur, Ignace Vergote, Domenica Lorusso, V. N. Trillet-Lenoir, Jean-Pierre Delord, Anna Petroccione, G. Locatelli, Patrick Schöffski, Elisa Gallerani
Publikováno v:
Journal of Clinical Oncology. 28:5014-5014
5014 Background: D is a small molecule that inhibits a urora kinases, proteins regulating mitosis implicated in tumorigenesis and overexpressed in BC and OC. Methods: In both tumor categories eligi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6446d7edf87e8b417090cb0edd2e14a1
https://doi.org/10.1200/jco.2010.28.15_suppl.5014
https://doi.org/10.1200/jco.2010.28.15_suppl.5014
Autor:
Emilio Bajetta, M.J.A. de Jonge, E. Endlicher, B. Laffranchi, R. Giuliani, Armando Santoro, C. Barone, A. Hendlisz, R. Spinelli, M. G. Jannuzzo
Publikováno v:
Journal of Clinical Oncology. 28:e13558-e13558
e13558 Background: D is a pan-aurora kinases inhibitor also active against other kinases with oncogenic potential, such as TRKA, RET, FGFRs, ABL. D has been showed to be active against a wide range...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e8ae5ee2a0dd80c3eb6778cb78387a0
https://doi.org/10.1200/jco.2010.28.15_suppl.e13558
https://doi.org/10.1200/jco.2010.28.15_suppl.e13558